MXPA05005314A - Compuestos de lapacona novedosos y metodos de uso de los mismos. - Google Patents
Compuestos de lapacona novedosos y metodos de uso de los mismos.Info
- Publication number
- MXPA05005314A MXPA05005314A MXPA05005314A MXPA05005314A MXPA05005314A MX PA05005314 A MXPA05005314 A MX PA05005314A MX PA05005314 A MXPA05005314 A MX PA05005314A MX PA05005314 A MXPA05005314 A MX PA05005314A MX PA05005314 A MXPA05005314 A MX PA05005314A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compounds
- lapachone compounds
- novel
- prevention
- Prior art date
Links
- QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical class C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006994 Precancerous Conditions Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/74—Naphthothiophenes
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42728302P | 2002-11-18 | 2002-11-18 | |
| PCT/US2003/037219 WO2004045557A2 (en) | 2002-11-18 | 2003-11-18 | Novel lapachone compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05005314A true MXPA05005314A (es) | 2005-10-19 |
Family
ID=34375156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05005314A MXPA05005314A (es) | 2002-11-18 | 2003-11-18 | Compuestos de lapacona novedosos y metodos de uso de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040266857A1 (enExample) |
| EP (1) | EP1567515A4 (enExample) |
| JP (1) | JP2006508147A (enExample) |
| CN (1) | CN1729183A (enExample) |
| AR (1) | AR056613A1 (enExample) |
| AU (1) | AU2003295738A1 (enExample) |
| BR (1) | BR0316296A (enExample) |
| CA (1) | CA2506340A1 (enExample) |
| EA (1) | EA200500849A1 (enExample) |
| MX (1) | MXPA05005314A (enExample) |
| TW (1) | TW200510367A (enExample) |
| WO (1) | WO2004045557A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004050033A2 (en) | 2002-12-02 | 2004-06-17 | Arqule, Inc. | Method of treating cancers |
| US7649013B2 (en) | 2003-11-26 | 2010-01-19 | Arqule, Inc. | Methods of protecting against radiation injury |
| WO2005082353A2 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for treating or preventing cancer |
| EP2033639A2 (en) | 2004-02-20 | 2009-03-11 | Arqule, Inc. | Beta-lapachone for the treatment of colon cancer |
| JP2007523190A (ja) * | 2004-02-20 | 2007-08-16 | アークル・インコーポレーテツド | 肺癌の治療のためのβ−ラパコンの使用 |
| EP2033638A2 (en) | 2004-02-20 | 2009-03-11 | Arqule, Inc. | Beta-lapachone for the treatment of pancreatic cancer |
| EP1722776A2 (en) * | 2004-02-20 | 2006-11-22 | Arqule, Inc. | Use of beta-lapachone as a broad spectrum anti-cancer agent |
| WO2005082357A1 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for treating hematologic tumors |
| US20050187288A1 (en) * | 2004-02-20 | 2005-08-25 | Chiang Li | Beta-lapachone and methods of treating cancer |
| EP1877097B1 (en) | 2004-08-11 | 2012-06-20 | Arqule, Inc. | Aminoacid conjugates of beta-lapachone for tumor targeting |
| US8614228B2 (en) | 2004-08-11 | 2013-12-24 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
| US20060204981A1 (en) | 2005-01-07 | 2006-09-14 | Chiang Li | Compositions for modulation of PARP and methods for screening for same |
| WO2006128120A2 (en) * | 2005-05-26 | 2006-11-30 | Arqule, Inc. | Novel lapachone compounds and methods of use thereof |
| JP2009538298A (ja) * | 2006-05-26 | 2009-11-05 | アークル インコーポレイテッド | 新規のラパコン化合物およびその使用方法 |
| TW200824692A (en) | 2006-08-21 | 2008-06-16 | Arqule Inc | Novel lapachone compounds and methods of use thereof |
| US8389568B2 (en) | 2007-03-16 | 2013-03-05 | Lankenau Institute For Medical Research | IDO inhibitors and methods of use thereof |
| ES2532656T3 (es) | 2007-04-30 | 2015-03-30 | Arqule, Inc. | Compuestos de hidroxi sulfonato de quinona y sus usos |
| US8067459B2 (en) | 2007-10-16 | 2011-11-29 | Arqule, Inc. | Lapachone compounds and methods of use thereof |
| KR101405823B1 (ko) | 2007-12-24 | 2014-06-12 | 주식회사 케이티앤지생명과학 | 녹내장의 치료 및 예방을 위한 약제 조성물 |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| KR20090073381A (ko) * | 2007-12-31 | 2009-07-03 | 주식회사 머젠스 | 심장질환의 치료 및 예방을 위한 약제 조성물 |
| RU2016140440A (ru) * | 2010-06-01 | 2018-12-14 | Белле-Эйр Фрейгренсиз, Инк. | Способ и продукт для борьбы с запахом изо рта |
| WO2017106624A1 (en) | 2015-12-18 | 2017-06-22 | The Board Of Regents Of The University Of Texas System | Napthoquinones, pro-drugs, and methods of use thereof |
| KR101735275B1 (ko) | 2016-12-20 | 2017-05-16 | 아주대학교산학협력단 | 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2011455B (en) * | 1977-12-21 | 1982-03-03 | Ici Ltd | Chemical process |
| US5346917A (en) * | 1991-06-10 | 1994-09-13 | Sterling Winthrop Inc. | Thioxanthenone antitumor agents |
| US5763625A (en) * | 1995-04-25 | 1998-06-09 | Wisconsin Alumni Research Foundation | Synthesis and use of β-lapachone analogs |
| US6245807B1 (en) * | 1995-08-24 | 2001-06-12 | Dana-Farber Cancer Institute | Treatment of human prostate disease |
| US5883270A (en) * | 1996-02-20 | 1999-03-16 | Wisconsin Alumni Research Foundation | 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth |
| US5824700A (en) * | 1996-02-20 | 1998-10-20 | Wisconsin Alumni Research Foundation | Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth |
| DE60031268T2 (de) * | 1999-04-14 | 2007-05-24 | Dana-Farber Cancer Institute, Inc., Boston | Verfahren und zusammansetzung zur behandlung von krebs |
| AU2003254029A1 (en) * | 2002-07-17 | 2004-02-02 | Arqule, Inc. | Activated checkpoint therapy and methods of use thereof |
-
2003
- 2003-11-18 BR BR0316296-6A patent/BR0316296A/pt not_active Application Discontinuation
- 2003-11-18 EA EA200500849A patent/EA200500849A1/ru unknown
- 2003-11-18 TW TW092132328A patent/TW200510367A/zh unknown
- 2003-11-18 WO PCT/US2003/037219 patent/WO2004045557A2/en not_active Ceased
- 2003-11-18 AU AU2003295738A patent/AU2003295738A1/en not_active Abandoned
- 2003-11-18 MX MXPA05005314A patent/MXPA05005314A/es not_active Application Discontinuation
- 2003-11-18 JP JP2004553999A patent/JP2006508147A/ja active Pending
- 2003-11-18 AR ARP030104253A patent/AR056613A1/es not_active Application Discontinuation
- 2003-11-18 EP EP03786941A patent/EP1567515A4/en active Pending
- 2003-11-18 CN CNA2003801066171A patent/CN1729183A/zh active Pending
- 2003-11-18 CA CA002506340A patent/CA2506340A1/en not_active Abandoned
-
2004
- 2004-03-26 US US10/810,260 patent/US20040266857A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR056613A1 (es) | 2007-10-17 |
| EP1567515A4 (en) | 2008-04-23 |
| WO2004045557A2 (en) | 2004-06-03 |
| US20040266857A1 (en) | 2004-12-30 |
| JP2006508147A (ja) | 2006-03-09 |
| TW200510367A (en) | 2005-03-16 |
| BR0316296A (pt) | 2005-12-13 |
| AU2003295738A1 (en) | 2004-06-15 |
| WO2004045557A3 (en) | 2004-08-12 |
| CN1729183A (zh) | 2006-02-01 |
| CA2506340A1 (en) | 2004-06-03 |
| EA200500849A1 (ru) | 2006-02-24 |
| EP1567515A2 (en) | 2005-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05005314A (es) | Compuestos de lapacona novedosos y metodos de uso de los mismos. | |
| IL260127B (en) | mek inhibitors and methods of using them | |
| IL181700A0 (en) | Quinazoline derivatives and pharmaceutical compositions containing the same | |
| MXPA05005223A (es) | Diaminotriazoles utiles como inhibidores de proteinas cinasas. | |
| GEP20094845B (en) | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | |
| AU2004263179A8 (en) | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain | |
| TW200510416A (en) | P38 inhibitors and methods of use thereof | |
| PH12012501372B1 (en) | Proteasome inhibitors and methods of using the same | |
| WO2006107451A3 (en) | Honokiol derivatives for the treatment of proliferative disorders | |
| AU2003225800A1 (en) | Azolylaminoazine as inhibitors of protein kinases | |
| AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
| AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
| PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| WO2004026253A3 (en) | Novel lapacho compounds and methods of use thereof | |
| IL171974A0 (en) | Tetrahydrocarbazole derivatives and their pharmaceutical use | |
| BRPI0411864A (pt) | combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
| UA89201C2 (ru) | Энантиомеры выбранных конденсированных пиримидонов и их применение для лечения и профилактики злокачественного новообразования | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| GB0407025D0 (en) | Novel compounds | |
| WO2006128120A3 (en) | Novel lapachone compounds and methods of use thereof | |
| ATE327240T1 (de) | 2ß OXO-VORUSCHARIN UND DERIVATEN | |
| UA96742C2 (en) | Mek inhibitors and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |